Skip to main content
SpringerLink
Log in

Pharmacodynamic and Pharmacokinetic Considerations in Choosing an Inhaled Corticosteroid

  • Review Article
  • Published:
Treatments in Respiratory Medicine

Abstract

Inhaled corticosteroids are effective in controlling airway inflammation. Their anti-inflammatory effect is primarily topical, at the site of deposition in the airways. Consequently, traditional pharmacodynamic and pharmacokinetic concepts, which rely on measuring blood concentrations of drug, have limited applicability for evaluating the efficacy of topically acting inhaled corticosteroids. Important factors affecting efficacy of inhaled corticosteroids are: (i) intrinsic properties of the drugs, particularly their affinity for the corticosteroid receptor; and (ii) the newer pharmacodynamic concept of deposition characteristics of the drug formulation. Small particle formulations, especially those developed in the metered-dose inhaler with the new hydrofluoroalkane propellant, deposit to a much greater extent in the lung and may consequently have improved clinical efficacy. Lipid conjugation of inhaled corticosteroids within the lung may allow prolonged duration of effect, enabling once-daily administration. Pharmacodynamic and pharmacokinetic principles probably do not play a role in describing upper airway adverse effects occurring with inhaled corticosteroids. These are probably also determined by intrinsic properties of the drug and deposition characteristics. However, pharmacodynamic and pharmacokinetic principles seem to be important in addressing systemic safety concerns with inhaled corticosteroids. Those inhaled corticosteroids with a longer serum half-life, especially if they have higher affinity for the corticosteroid receptor, may be associated with greater systemic effects. A new pharmacokinetic concept suggests that increased protein binding within the systemic circulation and high systemic clearance of an inhaled corticosteroid may reduce the risk for systemic effects. These new pharmacodynamic and pharmacokinetic concepts provide a useful framework for identifying the characteristics of an inhaled corticosteroid with an improved benefit-to-risk profile. Increased lung deposition and reduced deposition in the upper airway should result in an inhaled corticosteroid with favorable clinical efficacy and a decreased risk for topical upper airway adverse effects. An inhaled corticosteroid with high plasma protein binding and rapid clearance might pose much less risk for systemic adverse effects than currently available drugs in this class.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. Laitinen LA, Laitinen A, Haahtela T. Airway mucosal inflammation even in patients with newly diagnosed asthma. Am Rev Respir Dis 1993; 147: 697–704

    PubMed  CAS  Google Scholar 

  2. Vignola AM, Chanez P, Campbell AM, et al. Airway inflammation in mild intermittent and in persistent asthma. Am J Respir Crit Care Med 1998; 157: 403–9

    PubMed  CAS  Google Scholar 

  3. Hamid Q, Song Y, Kotsimbos TC, et al. Inflammation of small airways in asthma. J Allergy Clin Immunol 1997; 100: 44–51

    Article  PubMed  CAS  Google Scholar 

  4. Carroll N, Elliot J, Morton A, et al. The structure of large and small airways in nonfatal and fatal asthma. Am Rev Respir Dis 1993; 147: 405–10

    PubMed  CAS  Google Scholar 

  5. Busse WW, LeManske RF. Asthma. N Engl J Med 2001; 344: 350–62

    Article  PubMed  CAS  Google Scholar 

  6. Dorman SC, Sehmi R, Gauvreau GM, et al. Kinetics of bone marrow eosinophilopoiesis and associated cytokines after allergen inhalation. Am J Respir Crit Care Med 2004; 169: 565–72

    Article  PubMed  Google Scholar 

  7. Wood LJ, Sehmi R, Dorman SC, et al. Allergen-induced increases in bone marrow T lymphocytes and interleukin-5 expression in subjects with asthma. Am J Respir Crit Care Med 2004; 166: 883–9

    Article  Google Scholar 

  8. Expert Panel II. Guidelines for the diagnosis and management of asthma. Bethesda (MD): National Asthma Education and Prevention Program, 1997 Feb

  9. British guideline on the management of asthma. Thorax 2003; 52: il–i94

    Google Scholar 

  10. Boulet LP, Becker A, Berube D, et al. Canadian asthma consensus report, 1999. CMAJ 1999; 161: S1–S61

    PubMed  CAS  Google Scholar 

  11. National Asthma Campaign Australia. Asthma management handbook, 1998

  12. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. Am J Respir Crit Care Med 1998; 157: S1–S53

    PubMed  CAS  Google Scholar 

  13. Djukanovic R, Wilson JW, Britten KM, et al. Effects of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992; 148: 669–74

    Google Scholar 

  14. Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a β2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma. J Allergy Clin Immunol 1992; 90: 32–42

    Article  PubMed  CAS  Google Scholar 

  15. Trigg CJ, Manolitsas ND, Wang J, et al. Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. Am J Respir Crit Care Med 1994; 150: 17–22

    PubMed  CAS  Google Scholar 

  16. Allen DB, Bielory L, Derendorf H, et al. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 2003; 112: S1–S40

    Article  PubMed  CAS  Google Scholar 

  17. Lawrence M, Wolf J, Webb DR, et al. Efficacy of inhaled fluticasone propionate in asthma: results from topical and not systemic activity. Am J Respir Crit Care Med 1997; 156: 744–51

    PubMed  CAS  Google Scholar 

  18. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered dose inhaler compared to CFC-beclomethasone. Eur J Respir Dis 1998; 12: 1346–53

    Article  CAS  Google Scholar 

  19. Leach CL, Davidson PJ, Hasselquist BE, et al. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluoro-carbon fluticasone and chlorofluorocarbon beclomethasone. Chest 2002; 122: 510–6

    Article  PubMed  CAS  Google Scholar 

  20. Busse WW, Brazinsky S, Jacobson K, et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999; 104: 1215–22

    Article  PubMed  CAS  Google Scholar 

  21. Goldin JG, Tashkin DP, Kleerup EC, et al. Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways. J Allergy Clin Immunol 1999; 104: S258–67

    Article  PubMed  CAS  Google Scholar 

  22. Corren J, Nelson H, Greos LS, et al. Effective control of asthma with hydrofluoroalkane flunisolide delivered as an extrafine aerosol in asthma patients. Ann Allergy Asthma Immunol 2001; 87: 405–11

    Article  PubMed  CAS  Google Scholar 

  23. Shafazand S, Colice G. Flunisolide HFA for the treatment of asthma: an old friend reformulated. Expert Opin Pharmacother 2004; 5: 1163–73

    Article  PubMed  CAS  Google Scholar 

  24. Pelaia G, Vatrella A, Cuda G, et al. Molecular mechanisms of corticosteroid actions in chronic inflammatory airway diseases. Life Sci 2003; 72: 1549–61

    Article  PubMed  CAS  Google Scholar 

  25. Vachier I, Chiappara G, Vignola M, et al. Glucocorticoid receptors in bronchial epithelial cells in asthma. Am J Respir Crit Care Med 1998; 158: 963–70

    PubMed  CAS  Google Scholar 

  26. Colice GL. Comparing inhaled corticosteroids. Respir Care 2000; 45: 846–53

    PubMed  CAS  Google Scholar 

  27. Smith CL, Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittel Forschung 1998; 48: 956–60

    PubMed  CAS  Google Scholar 

  28. Stellate C, Atsuta J, Bickel CA, et al. An in vitro comparison of commonly used topical glucocorticoid preparations. J Allergy Clin Immunol 1999; 104: 623–9

    Article  Google Scholar 

  29. Aksoy MO, Li X, Borenstein M, et al. Effects of topical corticosteroids on inflammatory mediator-induced eicosanoid release by human airway epithelial cells. J Allergy Clin Immunol 1999; 103: 1081–91

    Article  PubMed  CAS  Google Scholar 

  30. Winkler J, Hochhaus G, Derendorf H. How the lung handles drugs. Proc Am Thorac Soc 2004; 1: 356–62

    Article  PubMed  CAS  Google Scholar 

  31. Szefler SJ, Martin ARJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002; 109: 410–8

    Article  PubMed  CAS  Google Scholar 

  32. Harrison LI, Colice GL, Donnell D, et al. Adrenal effects and pharmacokinetics of CFC-free beclomethasone dipropionate. J Pharm Pharmacol 1999; 51: 263–9

    Article  PubMed  CAS  Google Scholar 

  33. Holz O, Zuhlke I, Einhaus M, et al. Direct measurement of BDP and 17-BMP in bronchial and peripheral lung tissue after inhalation of HFA vs CFC-driven aerosols. Pulm Pharmacol Ther 2004; 17: 233–8

    Article  PubMed  CAS  Google Scholar 

  34. Fuller R, Johnson M, Bye A. Fluticasone propionate: an update on preclinical and clinical experience. Respir Med 1995; 89: S3–S18

    Article  Google Scholar 

  35. Esmailpur N, Hogger P, Rabe KF, et al. Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J 1997; 10: 1496–9

    Article  Google Scholar 

  36. Purucker M, Rosebraugh CJ, Zhou F, et al. Inhaled fluticasone propionate by diskus in the treatment of asthma: a comparison of the efficacy of the same nominal dose given either once or twice a day. Chest 2003; 124: 1584–93

    Article  PubMed  CAS  Google Scholar 

  37. Wieslander E, Delander EL, Jarkelid L, et al. Pharmacologic importance of the reversible fatty acid conjugation of budesonide studied in a rat cell line in vitro. Am J Respir Crit Care Med 1998; 19: 477–84

    CAS  Google Scholar 

  38. Physicians desk reference. 58th ed. Montvale (NJ): Thompson Publishing, 2004: 1504-1507

  39. Vander Burgt JA, Busse WW, Martin RJ, et al. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol 2000; 106: 1209–26

    Article  Google Scholar 

  40. Woodcock A. Use of spacers with metered dose inhalers. Lancet 1997; 349: 446

    Article  PubMed  CAS  Google Scholar 

  41. Martin RJ, Szefler SJ, Chinchilli VM, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 2002; 165: 1377–83

    Article  PubMed  Google Scholar 

  42. Reynolds NA, Scott LJ. Ciclesonide. Drugs 2004; 64: 511–9

    Article  PubMed  CAS  Google Scholar 

  43. Stoeck M, Riedel R, Hochhaus G, et al. In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide. J Pharmacol Exp Ther 2004; 309: 249–58

    Article  PubMed  CAS  Google Scholar 

  44. Kanniess F, Richter K, Bohme S, et al. Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma. Pulm Pharmacol Ther 2001; 14: 141–7

    Article  PubMed  CAS  Google Scholar 

  45. Weinbrenner A, Huneke D, Zschiesche M, et al. Circadian rhythm of serum Cortisol after repeated inhalation of the new topical steroid ciclesonide. J Clin Endocrinol Metab 2002; 87: 2160–3

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Although serving as consultant to various companies (Kos, Otsuka, Adams, Combinatorx, SanofiAventis, Altana, Pfizer, Boehringer Ingelheim, Almirall, and airPharma), the author has no current grant support relevant to this topic.

Author information

Authors and Affiliations

  1. Pulmonary, Critical Care and Respiratory Services, Washington Hospital Center, The George Washington University School of Medicine, 110 Irving St, NW, Washington, DC, 20010-2975, USA

    Gene L. Colice

Authors
  1. Gene L. Colice
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gene L. Colice.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Colice, G.L. Pharmacodynamic and Pharmacokinetic Considerations in Choosing an Inhaled Corticosteroid. Treat Respir Med 5, 245–253 (2006). https://doi.org/10.2165/00151829-200605040-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151829-200605040-00003

Keywords

Search

Navigation